All In Biotech

Free tool

FAERS Monitor: Yeztugo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220018 or its brand name (Yeztugo, Lenacapavir, Lenacapavir Sodium). Reports on generic versions are filed under their own applications.

Reports

506

Serious

127

25% of reports

Hospitalization

12

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site discharge149
  • injection site pain141
  • injection site nodule113
  • injection site erythema43
  • injection site mass37
  • injection site swelling24
  • injection site cellulitis17
  • loss of consciousness16
  • injection site bruising15
  • injection site reaction14
  • syncope13
  • nausea12
  • vomiting12
  • dizziness10
  • injection site discomfort10

Reports by year received

View as table
YearReports
20241
2025367
2026138

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,653 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
injection site dischargeSignal1491184.51032.3170,208
injection site noduleSignal113431.2366.247,606
injection site cellulitisSignal17383.8240.06,058
injection site massSignal3741.630.51,428
injection site discomfortSignal1039.621.4338
injection site painSignal14119.116.62,437
injection site erythemaSignal4314.410.8526
injection site swellingSignal2413.08.8255
injection site reactionSignal148.55.085
injection site bruisingSignal157.84.783
syncopeSignal135.43.243
loss of consciousnessSignal165.23.250
vomiting121.10.60
dizziness100.80.50
nausea120.60.42

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.